| Original language | English (US) |
|---|---|
| Pages (from-to) | 410-412 |
| Number of pages | 3 |
| Journal | Circulation |
| Volume | 139 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jan 15 2019 |
Keywords
- cholesterol
- clinical trial
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial : Insights From the Department of Veterans Affairs. / Virani, Salim S.; Akeroyd, Julia M.; Nambi, Vijay; Michos, Erin D.; Morris, Pamela B.; Nasir, Khurram; Smith, Sidney C.; Stone, Neil J.; Petersen, Laura A.; Ballantyne, Christie M.
In: Circulation, Vol. 139, No. 3, 15.01.2019, p. 410-412.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial
T2 - Insights From the Department of Veterans Affairs
AU - Virani, Salim S.
AU - Akeroyd, Julia M.
AU - Nambi, Vijay
AU - Michos, Erin D.
AU - Morris, Pamela B.
AU - Nasir, Khurram
AU - Smith, Sidney C.
AU - Stone, Neil J.
AU - Petersen, Laura A.
AU - Ballantyne, Christie M.
N1 - Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1- 14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. Funding Information: This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.
PY - 2019/1/15
Y1 - 2019/1/15
KW - cholesterol
KW - clinical trial
UR - http://www.scopus.com/inward/record.url?scp=85060035929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060035929&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.118.034993
DO - 10.1161/CIRCULATIONAHA.118.034993
M3 - Letter
C2 - 30586689
AN - SCOPUS:85060035929
VL - 139
SP - 410
EP - 412
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 3
ER -